By Howard Wolinsky, International Correspondent, The Active Surveillor
Australia has just redrawn its prostate‑cancer playbook, and the ripple effects may reach far beyond its borders.
What happened there is not a tweak — it’s a philosophical shift. A move toward earlier detection, smarter triage, and less fear. And yes, the digital rectal exam — the dreaded DRE — has been escorted off the stage.
“Australian men will benefit from new clinical practice guidelines on the early detection and management of prostate cancer,” said The Hon Mark Butler MP, Minister for Health and Ageing; Minister for Disability and the National Disability Insurance Scheme.
The government added that the guidelines aim to support earlier detection based on individual risk while reducing harms from overdiagnosis and overtreatment.
Australia’s new guidelines — developed by the Prostate Cancer Foundation of Australia and Cancer Council Australia — replace the 2016 version and reflect a decade of advances in imaging, biomarkers, and risk‑stratified care. The goal: catch dangerous cancers earlier while sparing men unnecessary biopsies, surgeries, and anxiety. Active Surveillance plays a stronger role than ever.
Australia’s new guidelines — developed by the Prostate Cancer Foundation of Australia and Cancer Council Australia — and made public Aug. 7 replace the 2016 version and reflect a decade of evidence and technological advances. They aim to catch dangerous cancers earlier while sparing men from unnecessary biopsies, surgeries, and anxiety. This is prostate care redesigned for the modern man: earlier, calmer, smarter. Active Surveillance is playing a stronger role in prostate care.
The heart of the change is simple: meet men where they are, not where the old rules left them. For decades, prostate cancer screening relied on men initiating the conversation — often too late. Now the system flips.
GPs will begin PSA discussions at age 45, not 50. That’s a cultural shift as much as a clinical one. It acknowledges that men often avoid talking about prostate health until symptoms appear — and by then, the disease may be more advanced.
If PSA rises, the next step is MRI, not a biopsy. This is one of the most patient‑friendly changes. MRI can show whether the PSA bump is just benign enlargement, sparing men from needles, pain, and fear. It’s a modern, humane triage system.
And the DRE? Gone from routine screening. Fear of the exam has long been the biggest barrier to men seeing their doctor. Removing it lowers the emotional threshold for care.
Men over 70 — previously excluded — will now continue PSA testing if they have a reasonable life expectancy. In a country where many 70‑year‑olds are active and healthy, this is a recognition of reality.
Australia is betting on a future where early detection doesn’t automatically mean overtreatment — a future built around Active Surveillance, individualized risk, and evidence‑based restraint.
And the DRE? Gone from routine screening. Fear of the exam has long been a major barrier to men seeing their doctor. Removing it lowers the emotional threshold for care.
Prostate cancer is the most commonly diagnosed cancer in Australia, with around 28,000 men diagnosed annually, and almost 4,000 men losing their lives each year.
Prof. Dorothy Keefe, MD, CEO of Cancer Australia, said: “The new clinical guidelines will help maximize the early detection of prostate cancer in Australian men. This approach closely aligns with the Australian Cancer Plan, which highlights the importance of personalized evidence-based early detection strategies.
“The work by the Royal Australian College of General Practitioners to raise doctors’ awareness of the new guidelines is a critical step to ensure their effective implementation.”
PCFA Chief Executive Anne Savage said: “These Guidelines provide Australia with an extraordinary opportunity to reduce deaths from our most commonly diagnosed cancer. Realizing that opportunity will require coordinated implementation, clinician education, consumer awareness, and ongoing investment in evidence-based care.”
The guidelines have been approved by the National Health and Medical Research Council and are available on the Prostate Cancer Foundation of Australia website.
Australia pushes PSA screening earlier, starting at age 45 for all men, with even earlier testing for high‑risk groups.
The American Urological Association, by contrast, recommends PSA screening mainly for men 50–69, with earlier discussions at 40–45 only for Black men and those with a family history. In short, Australia treats age 45 as the universal starting line, while the AUA reserves early screening for men at elevated risk.
MRI replaces biopsy-first — Elevated PSA leads to MRI, reducing unnecessary biopsies by about half. This idea is gaining traction in the U.S., but only about a third of American patients go this route.
Routine DRE removed — The exam that kept many men away is no longer part of standard screening.
Screening continues past 70 — Testing doesn’t stop at an arbitrary age; it follows life expectancy.
Risk-based testing — BRCA2 carriers, Black sub‑Saharan men, and those with family history get structured early testing.
GP training — Government-funded education ensures doctors can guide men through benefits, harms, and choices.
Active surveillance prioritized — Low-risk cancers are monitored, not rushed into treatment.
National consistency — One unified, evidence-based standard across the country.
Short answer: Yes — but slowly.
The US is decentralized. There is no national screening program. The US Preventive Services Task Force recommends PSA only as an individual choice for ages 55–69 and discourages screening after 70. MRI-first is growing but not universal. DRE still appears in some practices.
But Australia’s move will resonate here for three reasons:
Australia’s national endorsement strengthens the case for making MRI-first standard. Only about a third of U.S.patients get a prebiopsy MRI.
Australia’s removal of routine DRE may accelerate its decline in American clinics.
Australia’s universal age-45 start could push US clinicians to reconsider earlier testing for average-risk men.
Australia’s guidelines reinforce the global trend toward restraint.
When American men hear, like here, that Australians get MRI-first and no routine DRE, they will ask their doctors:
“Why not here?”
Check out my other Substack newsletter: This Guy’s Guide. It’s about aging and men’s health. The latest issue features my essay on “The Hinge Decade: Obama, Eastwood and the Rest of Us.” Give it a try.
By Howard Wolinsky, Editor, The Active Surveillor
Sir Chris Hoy shows up a couple minutes late for an interview in Glasgow, apologizing before he even sits down.
As The Guardian reports, he immediately launches into a story: a stranger stopped him on the street, newly diagnosed with prostate cancer, looking for strength.
Hoy understood the moment. He’s been living with stage‑4 prostate cancer for nearly three years, and he knows the emotional freefall that follows the words “you have cancer.”
“It’s so isolating when you get a cancer diagnosis,” he says. “You’re suddenly on borrowed time.”
His mission now is to make sure men facing the same news don’t feel alone — and to hammer home the scale of the disease. “10,000 [UK] men a year get the news that they have stage‑4 prostate cancer.”
In 2023, a nagging shoulder pain sent Hoy to his physiotherapist. A scan revealed a tumor. A second scan delivered the blow: the primary cancer was in his prostate and had already spread to his pelvis, hip, spine, ribs, and shoulder. He wrote in his memoir: “Just like that, I learn how I die.”
Doctors told him he likely had two to four years.
He still undergoes blood tests every three to six months, describing the dread of waiting for results. He remembers checking his PSA moments before stepping on stage for a sold‑out event: “Put your phone down, put a smile on and do it.”
Hoy admits that approaching the end of his third year of life‑expectancy is unsettling, but he refuses to let statistics define him:
“You have to remember the people outliving those statistics can’t be added to the data yet.”
He also speaks openly about loss. The death of journalist Dermot Murnaghan, who had hoped to ride with him for years to come, was a “huge shock.”
Last November, Hoy misjudged a jump while mountain biking in Wales. The crash shattered his tibial plateau; surgeons warned amputation was possible. A doctor friend looked at the X‑ray and told him: “That’s the kind of X‑ray you’ll see when someone’s parachute hasn’t deployed.”
Recovery was “miserable,” but mountain biking remains essential to him — physically, mentally, socially. Being outdoors keeps him grounded.
Across both accounts, Hoy’s identity as an athlete isn’t nostalgia — it’s survival. He still rides, still trains, still pushes himself. He completed a 750‑kilometer Pyrenees ride this summer. He worked the Commonwealth Games. He led the Tour de 4 charity ride, raising £3.1 million, and rode alongside Miguel Induráin, his boyhood hero, calling it “a huge honor to be with him.”
The Mirror’s latest coverage highlights Hoy’s belief that movement is central to his resilience. He told The Big Issue:
“Exercise is a big part of my dealing with my cancer… If it was in pill form, it would be hailed as a miracle drug.”
He cites research showing physical activity can boost the effectiveness of cancer treatments and extend time to relapse. More than that, exercise gives him purpose — a way to reclaim agency in a diagnosis that initially felt devoid of hope.
“It took a long time to find any positivity or opportunity from that really difficult situation,” he says. “For me, that was saying maybe we can change attitudes to stage‑4 cancer.”
Hoy wants men to understand risk, get tested, and know they’re not alone. He wants to change how people think about late‑stage cancer — to show that strength, endurance, connection, and joy are still possible.
He’s still sprinting toward that goal.
A fast‑moving area of prostate cancer research is gaining attention: the gut microbiome and its potential connection to prostate cancer. Early studies suggest gut bacteria may influence inflammation, metabolism, immune activity — even patterns seen in prostate cancer itself.
Join ASPI for a look at what researchers actually know — and what remains speculation — with urologic oncologist Dr. Michael Liss of UC San Diego, a leading voice in microbiome research and prostate cancer innovation.
Webinar: Saturday, August 22, 2026 • 12 PM Eastern
Where: Zoom — Register here: https://aspatients.org/event/gut-microbiome-prostate-cancer/
Why not get a paid subscription and help me cover my overhead? The Active Surveillor is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.